<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1209234194
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZEVTERA 500 mg Powder for concentration for Solution for Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTOBIPROLE MEDOCARIL SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1836.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Nipro Pharma Corporation Ise Plant" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Nipro Pharma Corporation Ise Plant
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DI01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zevtera is an antibiotic medicine that contains the active substance ceftobiprole medocaril sodium. It belongs to a group of medicines called &lsquo;cephalosporin antibiotics&rsquo;.</p><p>Zevtera is used to treat term neonates, infants, children, adolescents, and adults with infections of the lungs called &lsquo;pneumonia&rsquo;.</p><p>Zevtera works by killing certain bacteria, which can cause serious lung infections.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Zevtera:</strong></p><ul><li>If you are allergic to ceftobiprole medocaril sodium or any of the other ingredients of this medicine (listed in section 6),</li><li>If you are allergic to other cephalosporin or beta-lactam antibiotics,</li><li>If you have had previous severe allergic reactions to other antibiotics like penicillin or carbapenem.</li></ul><p>Do not use Zevtera if any of the above applies to you. If you are not sure, talk to your doctor or nurse before being given Zevtera.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or nurse before using Zevtera:</p><ul><li>If you have kidney problems (your doctor may need to lower your dose of this medicine),</li><li>If you have ever had any allergic reactions to other antibiotics like penicillin or carbapenem,</li><li>If you have ever had fits (seizures or convulsions),</li><li>If you have diarrhoea before, during or after your treatment with this medicine (you may have an inflammation of the bowel known as &lsquo;colitis&rsquo;). Do not take any medicine to treat diarrhoea without first checking with your doctor,</li><li>If you are HIV positive,</li><li>If your immune system is severely weakened,</li><li>If your white blood counts are very low or your bone marrow function is suppressed,</li><li>If your lung infection is developed more than 48 hours after onset of artificial ventilation Zevtera is not suitable for you (your doctor will prescribe a suitable antibiotic for you),</li><li>If you require (or are expected to require) concomitant calcium-containing solutions, except Lactated Ringer&rsquo;s solution for injection, in the same intravenous administration line due to the risk of precipitation.</li></ul><p>If your doctor thinks you need more fluids, you may be asked to drink plenty of liquids or you may need to have liquids given as a drip into a vein while you are receiving Zevtera.</p><p>If you start taking Zevtera and then require ventilation, your doctor will assess whether Zevtera is still suitable for you.</p><p><em>Lab tests</em></p><p>You may develop an abnormal lab test (called Coombs test) that looks for certain antibodies which may act against your red blood cells. Zevtera may also interact with tests to measure serum creatinine (Jaff&eacute; reaction) or with some tests to determine the glucose content in the urine. These tests may provide you with wrong results.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or nurse before using Zevtera.</p><p><strong>Children</strong></p><p>Zevtera is not recommended for use in preterm newborns (born prematurely) as safety and efficacy in this age group have not been established<strong>.</strong></p><p><strong>Other medicines and Zevtera</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p><strong>Driving and using machines </strong></p><p>Zevtera may cause side effects such as dizziness. This may impair your ability to drive or operate machinery.</p><p><strong>Zevtera</strong><strong> </strong><strong>contains sodium</strong></p><p>Zevtera contains sodium.<strong> </strong>Zevtera 500 mg Powder for Concentrate for Solution for Infusion contains approximately 1.3 mmol (29 mg) sodium per dose. If you have a controlled sodium diet, your doctor may need to adjust it</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zevtera will be given to you by a doctor or nurse.</p><p>The recommended dose for adults is 500 mg ceftobiprole every&nbsp; 8 hours given as a drip into a vein lasting 2 hours.</p><p>The recommended dose for term neonates, infants, children and adolescents depends on the age and weight of the child and is given every 8 hours (infants aged 3 months or older, children and adolescents) or every 12 hours (term neonates and infants younger than 3 months) as a drip into a vein lasting 2 hours.</p><p>The infusion solution with a ceftobiprole concentration of 2 mg/ml is used for adults and adolescents. For infants and term neonates, the infusion solution with a ceftobiprole concentration of 4 mg/ml is used.</p><p>Patients with kidney problems</p><p>You may need a lower dose of Zevtera if you have kidney problems.</p><p><strong>If you use more Zevtera than you should</strong></p><p>If you think you have been given too much Zevtera, talk to your doctor or nurse straight away.</p><p><strong>If you forget to use Zevtera</strong></p><p>If you think you have missed a dose, talk to your doctor or nurse straight away.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>Tell your doctor straight away if you get these symptoms as you may need urgent medical treatment:</p><ul><li>Sudden swelling of your lips, face, throat or tongue; a severe rash; and, swallowing or breathing problems. These may be signs of a severe allergic reaction (anaphylaxis) and may be life threatening.</li><li>Diarrhoea that becomes severe or does not go away or stool that contains blood or mucus during or after treatment with Zevtera. In this situation, you should not take medicines that stop or slow bowel movement.</li></ul><p>Common: may affect up to 1 in 10 people</p><ul><li>Feeling sick (nausea)</li><li>Headache, drowsiness (somnolence)</li><li>Feeling dizzy</li><li>Rash, itching or hives</li><li>Diarrhoea, tell your doctor straight away if you get diarrhoea</li><li>Being sick (vomiting)</li><li>Stomach pain (abdominal pain), indigestion or &lsquo;heartburn&rsquo; (dyspepsia)</li><li>Unusual taste (dysgeusia)</li><li>Fungal infections in different parts of your body</li><li>Redness, pain or swelling were the injection was given</li><li>Low levels of the mineral &lsquo;sodium&rsquo; in your blood</li><li>Increase in the level of some liver enzymes in your blood</li><li>Hypersensitivity including skin reddening</li></ul><p>Uncommon: may affect up to 1 in 100 people</p><ul><li>Convulsions, seizures, or fits</li><li>Temporarily decreased or increased numbers of certain types of blood cells</li><li>Blood testing showing decreased levels of potassium</li><li>Sleeplessness and sleep disturbances, maybe including anxiety, panic attacks and nightmares</li><li>Shortness of breath or difficulty breathing, asthma</li><li>Muscle cramps</li><li>Kidney problems</li><li>Swelling, particularly of the ankles and legs</li><li>Blood testing showing temporarily increased levels of triglycerides, blood sugar or creatinine</li></ul><p>Not known: frequency cannot be estimated from the available data</p><ul><li>&middot;&nbsp;&nbsp;&nbsp; A more severe decrease in a specific type of white blood cells (agranulocytosis)</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package in order to protect from light.</p><p>For storage of Zevtera reconstituted and diluted infusion solutions, please see the accompanying information for medical or healthcare professionals.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is ceftobiprole medocaril sodium.</p><p>Each vial contains 666.6 mg ceftobiprole medocaril sodium equivalent to 500 mg ceftobiprole.</p><p>After reconstitution, each 1 ml of concentrate contains 66.7 mg ceftobiprole medocaril sodium equivalent to 50 mg ceftobiprole.</p><p>The other ingredients are citric acid monohydrate and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zevtera 500 mg Powder for Concentrate for Solution for Infusion is a white, yellowish to slightly brownish, cake to broken cake or powder in 20 ml clear glass vials fitted with grey elastomeric closures and aluminum seals with plastic flip-off caps. 

After reconstitution, clear to slightly opalescent, yellowish solution, free from visible foreign material. 

Pack size: 10 Vials.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong></p><p>Nipro Pharma Corporation - Odate Plant</p><p>5-7, Niida Aza Maedano</p><p>Odate - Shi, Akita, 018-5751</p><p>Japan</p><p><strong>Under license from</strong></p><p>Basilea Pharmaceutica International Ltd., Allschwil</p><p>Hegenheimermattweg 167b<br />4123 Allschwil<br />Switzerland</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 10/2023; version number Un2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">زيڤتيرا مضاد حيوي يحتوي على المادة الفعالة سيفتوبيبرول ميدوكاريل الصوديوم. وينتمي إلى مجموعة الأدوية التي تُسمى &rsquo;المضادات الحيوية السيفالوسبورينية&lsquo;. &nbsp;</p><p dir="RTL">يستخدم زيڤتيرا لعلاج حديثي الولادة، الرضع، الأطفال، المراهقين، والبالغين المصابين بحالات عدوى الرئتين والتي يُطلق عليها &rsquo;الالتهاب الرئوي&lsquo;.</p><p dir="RTL">يعمل زيڤتيرا على قتل نوع معين من البكتيريا، التي تسبب عدوى رئوية خطيرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم زيڤتيرا: </strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لسيفتوبيبرول ميدوكاريل الصوديوم أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6)،</li><li>إذا كنت تعاني من حساسية للمضادات الحيوية السيفالوسبورينية أو للمضادات الحيوية من مجموعة البيتا-لاكتام الأخرى،</li><li>إذا عانيت سابقاً من ردود فعل تحسسية شديدة للمضادات الحيوية الأخرى مثل البنيسيلين أو الكاربابينيم.</li></ul><p dir="RTL">لا تستخدم زيڤتيرا إذا كان ينطبق عليك أي مما سبق. إذا لم تكن متأكداً، فاستشر طبيبك أو الممرض قبل أن يتم إعطاؤك زيڤتيرا.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث مع طبيبك، أو الممرض قبل استخدام زيڤتيرا:</p><ul dir="rtl"><li>إذا كنت تعاني من مشاكل في الكلى (قد يحتاج طبيبك لتقليل جرعتك من هذا الدواء)،</li><li>إذا تعرضت من قبل لأي ردود فعل تحسسية للمضادات الحيوية الأخرى مثل البنيسيلين أو الكاربابينيم،</li><li>إذا تعرضت من قبل لنوبات (نوبات تشنجية أو اختلاجات)،</li><li>إذا عانيت من إسهال قبل، أثناء أو بعد العلاج بهذا الدواء (قد تكون مصابًا بالتهاب في الأمعاء يعرف باسم &rsquo;التهاب القولون&lsquo;). لا تتناول أي دواء لعلاج الإسهال دون الرجوع إلى طبيبك أولاً،</li><li>إذا كنت مصاباً بفيروس العوز المناعي البشري،</li><li>إذا كان جهازك المناعي يعاني من ضعف شديد،</li><li>إذا كان عدد كريات الدم البيضاء منخفض جداً أو تعاني من تثبيط في عمل نقي العظم،</li><li>إذا تطورت لديك عدوى الرئة بعد أكثر من 48 ساعة من بداية التنفس الاصطناعي، حيث لا يكون زيڤتيرا مناسباً لك (سيصف طبيبك المضاد الحيوي المناسب لك)،</li><li>إذا كنت تحتاج (أو من المتوقع أن تحتاج) لأخذ محاليل تسريب مصاحبة تحتوي على الكالسيوم، باستثناء محلول الحقن رينغر اللاكتاتي في نفس المسار الوريدي، وذلك بسبب خطر حدوث الترسب.</li></ul><p dir="RTL">إذا كان طبيبك يعتقد بأنك تحتاج لمزيد من السوائل، فقد يُطلب منك تناول مقدار وافر من السوائل أو قد تحتاج لسوائل يتم إعطاؤها بالتنقيط في الوريد أثناء تلقيك زيڤتيرا.</p><p dir="RTL">إذا بدأت في استخدام زيڤتيرا ومن ثم احتجت للتنفس الاصطناعي، فسوف يقوم طبيبك بتقييم ما إذا كان زيڤتيرا لا يزال مناسباً لك أم لا.</p><p dir="RTL"><em>الفحوصات </em><em>المخبرية</em></p><p dir="RTL">قد تظهر نتائج غير طبيعية في أحد الفحوصات المخبرية (يسمى اختبار كومس) والذي يتحقق من أجسام مضادة معينة تقاوم خلايا الدم الحمراء. وقد يتداخل زيڤتيرا أيضاً مع اختبارات قياس الكرياتينين في مصل الدم (تفاعل جافيه) أو بعض اختبارات تحديد محتوى الجلوكوز في البول. قد تعطيك هذه الاختبارات نتائج خاطئة.</p><p dir="RTL">إذا كان ينطبق عليك أي مما سبق (أو إذا لم تكن متأكداً)، فاستشر طبيبك أو الممرض قبل استخدام زيڤتيرا.</p><p dir="RTL"><strong>الأطفال </strong></p><p dir="RTL">لا يوصى باستخدام زيڤتيرا للخدج حديثي الولادة (ولد مُبكرا) حيث لم يتم إثبات السلامة والفعالية في هذه الفئة العمرية.</p><p dir="RTL"><strong>الأدوية الأخرى وزيڤتيرا</strong></p><p dir="RTL">أخبر طبيبك أو الممرض إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">اطلبي النصيحة من طبيبك قبل استخدام هذا الدواء، إذا كنت حاملاً أو مرضع، تعتقدين بأنك حاملٌ أو تخططين لذلك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب زيڤتيرا آثاراً جانبية مثل الدوخة. قد يُضعف هذا من قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL"><strong>يحتوي زيڤتيرا على الصوديوم</strong></p><p dir="RTL">يحتوي زيڤتيرا على الصوديوم. يحتوي زيڤتيرا 500 ملغم مسحوق لتشكيل المركز ثم التخفيف للتسريب على 1.3 ملمول (29 ملغم) تقريباً من الصوديوم لكل جرعة. إذا كنت تتبع نظاماً غذائياً مضبوط الصوديوم، فقد يحتاج طبيبك إلى تعديله</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك زيڤتيرا من قبل طبيبك أو الممرض.</p><p dir="RTL">الجرعة الموصى بها للبالغين هي 500 ملغم من سيفتوبيبرول كل 8 ساعات ويتم إعطاؤها عن طريق التنقيط في الوريد لمدة ساعتين.</p><p dir="RTL">تعتمد الجرعة الموصى بها لحديثي الولادة، الرضع، الأطفال والمراهقين على عمر ووزن الطفل ويتم إعطاؤها كل 8 ساعات (الرضع بعمر 3 أشهر أو أكثر، الأطفال والمراهقين) أو كل 12 ساعة (حديثي الولادة والرضع الأصغر من 3 أشهر) بالتنقيط في الوريد لمدة ساعتين.</p><p dir="RTL">يستخدم محلول التسريب سيفتوبيبرول بتركيز 2 ملغم/مللتر للبالغين والمراهقين. بالنسبة للرضع وحديثي الولادة، يتم استخدام محلول التسريب سيفتوبيبرول بتركيز 4 ملغم/مللتر.</p><p>المرضى الذين يعانون من مشاكل في الكلى</p><p dir="RTL">قد تحتاج إلى جرعة أقل من زيڤتيرا إذا كنت تعاني من مشاكل في الكلى.</p><p dir="RTL"><strong>إذا استخدمت زيڤتيرا أكثر من اللازم</strong></p><p dir="RTL">إذا كنت تعتقد أنك قد تم إعطاؤك جرعة زائدة من زيڤتيرا، فتحدث مع طبيبك أو الممرض في الحال.</p><p dir="RTL"><strong>إذا نسيت استخدام </strong><strong>زيڤتيرا</strong></p><p dir="RTL">إذا كنت تعتقد أنك قد فاتك جرعة، فتحدث مع طبيبك أو الممرض في الحال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء. قد تحدث الآثار الجانبية التالية عند تناول هذا الدواء:</p><p>أخبر طبيبك في الحال إذا ظهرت لديك هذه الأعراض حيث قد تحتاج إلى علاج طبي عاجل:</p><ul dir="rtl"><li>تورم مفاجئ في الشفتين، الوجه، الحلق أو اللسان؛ طفح شديد؛ ومشاكل في البلع أو التنفس. قد تكون هذه علامات لرد فعل تحسسي شديد (تَأَقّ) وقد تهدد الحياة.</li><li>الإسهال الذي يصبح شديداً أو لا يتوقف أو البراز الذي يحتوي على الدم أو المخاط أثناء العلاج بزيڤتيرا أو بعده. في هذه الحالة، يجب عدم تناول الأدوية التي تؤدي إلى توقف حركة الأمعاء أو إبطائها.</li></ul><p>شائعة: قد تصيب ما يصل إلى شخص من بين كل 10 أشخاص</p><ul dir="rtl"><li>الغثيان</li><li>الصداع، النعاس (النيمومة)</li><li>الشعور بالدوخة</li><li>طفح، حكة أو شرى</li><li>إسهال، أخبر طبيبك في الحال إذا أصبت بإسهال</li><li>القيء</li><li>ألم في المعدة (ألم في البطن)، عسر الهضم أو &rsquo;حرقة في المعدة&lsquo;</li><li>تذوق غير عادي (خَلَلُ الذَّوق)</li><li>عدوى فطرية في أجزاء مختلفة من الجسم</li><li>احمرار، ألم أو تورم في موضع الحقن</li><li>انخفاض مستويات معدن الصوديوم في الدم</li><li>زيادة في مستوى بعض إنزيمات الكبد في الدم</li><li>فرط التحسس بما في ذلك احمرار الجلد</li></ul><p>غير شائعة: قد تصيب ما يصل إلى شخص من بين كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الاختلاجات، النوبات التشنجية أو النوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; انخفاض أو زيادة مؤقتة في أعداد أنواع معينة من خلايا الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اختبار الدم يظهر انخفاض مستويات البوتاسيوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الأرق واضطرابات النوم، قد يشمل ذلك القلق، نوبات الهلع والكوابيس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ضيق النفس أو صعوبة في التنفس، الربو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تشنجات عضلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; مشاكل في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تورُّم، خصوصاً في الكاحلين والساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; اختبار الدم يظهر زيادة مؤقتة في مستويات ثلاثي الجليسريد، السكر في الدم أو الكرياتينين</p><p>&nbsp;</p><p>غير معروفة: لا يمكن تقدير تكرارها من البيانات المتوفرة</p><ul><li>&middot;&nbsp;&nbsp;&nbsp; انخفاض أكثر شدة في نوع معين من خلايا الدم البيضاء (ندرة المحببات</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ داخل الثلاجة (2-8&deg; مئوية).</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">لحفظ محاليل التسريب التي تم حلها وتخفيفها لزيڤتيرا، يُرجى النظر إلى المعلومات المقدمة إلى متخصصي الرعاية الطبية أو الصحية المرفقة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي سيفتوبيبرول ميدوكاريل الصوديوم.</p><p dir="RTL">تحتوي كل زجاجة على 666.6 ملغم سيفتوبيبرول ميدوكاريل الصوديوم يكافئ 500 ملغم سيفتوبيبرول. &nbsp;</p><p dir="RTL">بعد الحل، يحتوي كل 1 مللتر من المحلول المركز على 66.7 ملغم سيفتوبيبرول ميدوكاريل الصوديوم يكافئ 50 ملغم سيفتوبيبرول.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي حمض السيتريك أحادي الماء وهيدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">زيڤتيرا 500 ملغم مسحوق لتشكيل المركز ثم التخفيف للتسريب هو كتلة إلى كتل متكسرة أو مسحوق ذات لون أبيض، مصفر مائل قليلاً إلى البني في زجاجات شفافة بحجم 20 مللتر مزودة بسدادات مطاطية رمادية اللون ومحكمة الإغلاق بغلاف من مادة الألمنيوم وأغطية بلاستيكية قابلة للفتح لأعلى.</p><p dir="RTL">بعد الحل، محلول صافٍ إلى فيه غباش قليلاً، مصفرّ اللون، خالٍ من المواد الغريبة المرئية.</p><p dir="RTL">حجم العبوة: 10 زجاجات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com<strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة نيبرو الدوائية - مصنع أوديت</p><p dir="RTL">7-5، نيدا آزا مايدانو</p><p dir="RTL">أوديت - شي، أكيتا، 5751-018</p><p>اليابان</p><p dir="RTL"><strong>بترخيص من</strong></p><p dir="RTL">شركة بازيليا العالمية للصناعات الدوائية المحدودة، ألشويل</p><p dir="RTL">هيغنهايمرماتويغ 167b</p><p dir="RTL">4123 ألشويل</p><p dir="RTL">سويسرا<br />&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p>المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 10/2023؛ رقم النسخة Un2.0.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zevtera 500 mg Powder for Concentrate for Solution for Infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 666.6 mg ceftobiprole medocaril sodium equivalent to 500 mg ceftobiprole. 

After reconstitution, each 1 ml of concentrate contains 66.7 mg ceftobiprole medocaril sodium equivalent to 50 mg ceftobiprole.

Excipient with known effect: Sodium.

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.

White, yellowish to slightly brownish, cake to broken cake or powder.

After reconstitution, clear to slightly opalescent, yellowish solution, free from visible foreign material. 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zevtera is indicated for the treatment of the following infections in adults, term neonates, infants, children and adolescents (see sections 4.4 and 5.1):</p><ul><li>Hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP)</li><li>Community-acquired pneumonia (CAP)</li></ul><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>The recommended regimen for adult and paediatric patients with normal renal function is shown in Table 1.</p><p>Table 1: Dosage in adult and paediatric patients with normal renal function or mild renal impairment (i.e., creatinine clearance [CL<sub>CR</sub>] &ge; 50 mL/min)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Age group</strong></p></td><td style="vertical-align:top"><p><strong>Body weight (kg)</strong></p></td><td style="vertical-align:top; width:166px"><p><strong>Ceftobiprole dose</strong></p></td><td style="vertical-align:top; width:364px"><p><strong>Concentration of infusion solution<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Infusion time/ Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adults</strong></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top; width:166px"><p>500 mg</p></td><td rowspan="3" style="width:364px"><p>2 mg/mL</p></td><td rowspan="3"><p>2 h infusion / every 8 hours</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Adolescents</strong></p><p><strong>aged 12 to &lt; 18 years</strong></p></td><td style="vertical-align:top"><p>&ge; 50 kg</p></td><td style="vertical-align:top; width:166px"><p>500 mg</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 50 kg</p></td><td style="vertical-align:top; width:166px"><p>10 mg/kg</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Infants</strong></p><p><strong>aged &ge; 3 months and children &lt; 12 years</strong></p></td><td style="vertical-align:top"><p>&ge; 33 kg</p></td><td style="vertical-align:top; width:166px"><p>500 mg</p></td><td rowspan="4" style="width:364px"><p>4 mg/mL</p></td><td rowspan="2"><p>2 h infusion / every 8 hours</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 33 kg</p></td><td style="vertical-align:top; width:166px"><p>15 mg/kg</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Term neonates and infants &lt; 3 months</strong></p></td><td style="vertical-align:top"><p>&ge; 4 kg</p></td><td style="vertical-align:top; width:166px"><p>15 mg/kg</p></td><td rowspan="2"><p>2 h infusion / every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 4 kg</p></td><td style="vertical-align:top; width:166px"><p>10 mg/kg</p></td></tr></tbody></table><p><sup>a</sup> See section 6.6.</p><p>For adult and paediatric patients aged &ge; 12 years, the ceftobiprole concentration of the infusion solution is 2 mg/ml. To limit the infusion volume for paediatric patients &lt; 12 years of age, the ceftobiprole concentration of the infusion solution for these patients is 4 mg/ml.</p><p>For CAP, a switch to an appropriate oral antibiotic may be considered after completion of at least 3 days of intravenous ceftobiprole medocaril sodium treatment, depending on the patient&rsquo;s clinical response.</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Zevtera in preterm neonates have not been established. Zevtera is not recommended for use in preterm neonates.</p><p><u>Special populations</u></p><p><em>Elderly patients</em></p><p>No dose adjustment is necessary in elderly patients, except in cases of moderate to severe renal impairment (see below and section 5.2).</p><p><em>Renal impairment and end-stage renal disease requiring dialysis</em></p><p>In adult and paediatric patients with mild renal impairment (i.e., CL<sub>CR</sub>&nbsp;50 to 80 ml/min), no dosage adjustment is necessary. In adult and paediatric patients with moderate renal impairment (CL<sub>CR</sub> 30 to &lt; 50 ml/min), adult and paediatric patients with severe renal impairment (CL<sub>CR</sub> 10 ml/min to &lt; 30 mL/min), and adult patients with end-stage renal disease (ESRD) requiring dialysis, the dosage of Zevtera should be adjusted as shown in Table 2. There is insufficient information to recommend dosage adjustments in paediatrics patients with end-stage renal disease (ESRD).</p><p><strong>Table 2: Dosage in adult and paediatric patients with moderate renal impairment (CL<sub>CR</sub> 30 to &lt;50 mL/min), severe renal impairment (CL<sub>CR</sub> &lt;30 mL/min), or patients with ESRD requiring dialysis</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:1209px"><tbody><tr><td style="vertical-align:top; width:488px"><p><strong>Age group</strong></p></td><td style="vertical-align:top; width:15px"><p><strong>Creatinine clearance, CL<sub>CR</sub>&nbsp;(ml/min)<sup>a</sup></strong></p></td><td style="vertical-align:top; width:231px"><p><strong>Ceftobiprole dose</strong></p></td><td style="vertical-align:top; width:323px"><p><strong>Concentration of infusion solution<sup>d</sup></strong></p></td><td style="vertical-align:top; width:208px"><p><strong>Infusion time (hours)/ Frequency</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:488px"><p>Adults</p></td><td style="vertical-align:top; width:15px"><p>30 to &lt; 50</p></td><td style="vertical-align:top; width:231px"><p>500 mg</p></td><td rowspan="5" style="width:323px"><p>2 mg/ml</p></td><td rowspan="2" style="width:208px"><p>2 h infusion / every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:15px"><p>10 to &lt; 30</p></td><td style="vertical-align:top; width:231px"><p>250 mg</p></td></tr><tr><td style="vertical-align:top; width:15px"><p>ESRD, including haemodialysis<sup>b</sup></p></td><td style="width:231px"><p>250 mg</p></td><td style="width:208px"><p>2 h infusion / every 24 hours</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:488px"><p>Adolescents</p><p>Aged 12 to &lt; 18 years</p></td><td style="vertical-align:top; width:15px"><p>30 to &lt; 50</p></td><td style="vertical-align:top; width:231px"><p>7.5 mg/kg</p></td><td rowspan="2" style="width:208px"><p>2 h infusion / every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:15px"><p>10 to &lt; 30</p></td><td style="vertical-align:top; width:231px"><p>7.5 mg/kg<sup>c</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:488px"><p>Children aged 6 to &lt; 12 years</p></td><td style="vertical-align:top; width:15px"><p>30 to &lt; 50</p></td><td style="vertical-align:top; width:231px"><p>7.5 mg/kg</p></td><td rowspan="8" style="width:323px"><p>4 mg/ml</p></td><td style="vertical-align:top; width:208px"><p>2 h infusion / every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:15px"><p>10 to &lt; 30</p></td><td style="vertical-align:top; width:231px"><p>7.5 mg/kg<sup>c</sup></p></td><td style="vertical-align:top; width:208px"><p>2 h infusion / every 24 hours</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:488px"><p>Infants</p><p>aged &ge; 3 months and children &lt; 6 years</p></td><td style="vertical-align:top; width:15px"><p>30 to &lt; 50</p></td><td style="vertical-align:top; width:231px"><p>10 mg/kg</p></td><td style="vertical-align:top; width:208px"><p>2 h infusion / every 12 hours</p></td></tr><tr><td style="width:15px"><p>10 to &lt; 30</p></td><td style="width:231px"><p>10 mg/kg</p></td><td style="width:208px"><p>2 h infusion / every 24 hours</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:488px"><p>Term neonates and infants &lt; 3 months, bodyweight &ge; 4 kg</p></td><td style="vertical-align:top; width:15px"><p>30 to &lt; 50</p></td><td style="vertical-align:top; width:231px"><p>15 mg/kg</p></td><td style="vertical-align:top; width:208px"><p>2 h infusion / every 12 hours</p></td></tr><tr><td style="width:15px"><p>10 to &lt; 30</p></td><td style="width:231px"><p>15 mg/kg</p></td><td style="width:208px"><p>2 h infusion / every 24 hours</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:488px"><p>Term neonates and infants &lt; 3 months, bodyweight &lt; 4 kg</p></td><td style="width:15px"><p>30 to &lt; 50</p></td><td style="width:231px"><p>10 mg/kg</p></td><td style="width:208px"><p>2 h infusion / every 12 hours</p></td></tr><tr><td style="width:15px"><p>10 to &lt; 30</p></td><td style="width:231px"><p>10 mg/kg</p></td><td style="width:208px"><p>2 h infusion / every 24 hours</p></td></tr></tbody></table><p>Note: All regimen administered as a 2 h infusion with a maximum allowable dose of 500 mg regardless of patient&#39;s weight unless otherwise specified.</p><p><sup>a</sup>&nbsp;Calculated in ml/min/1.73 m<sup>2</sup>&nbsp;using the Schwartz formula for paediatric patients. CL<sub>CR</sub>&nbsp;should be closely monitored and the dose adjusted according to changing renal function.</p><p><sup>b</sup>&nbsp;Ceftobiprole medocaril sodium is haemodialysable; thus Zevtera should be administered after haemodialysis on haemodialysis days.</p><p><sup>c</sup>&nbsp;Up to a maximum dose of 250 mg.</p><p><sup>d</sup>&nbsp;See section 6.6.</p><p>Dose recommendations for term neonates, infants, children, and adolescents are based on pharmacokinetic modelling. Due to limited clinical data and an expected increased exposure of Zevtera and its metabolite, Zevtera should be used with caution in patients with severe renal impairment (see section 5.2).</p><p><em>Patients with creatinine clearance &gt; 150 ml/min</em></p><p>At start of treatment the prescribing physician should assess the renal function of the patient based on creatinine clearance expressed in ml/minute<em>.</em></p><p>In patients with a supra-normal creatinine clearance (&gt; 150 ml/min), based on pharmacokinetic/pharmacodynamic considerations, prolongation of the infusion duration to 4 hours is recommended (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>There is no experience in patients with hepatic impairment. However, as ceftobiprole undergoes minimal hepatic metabolism and is eliminated predominantly by the kidneys, no dosage adjustment is considered necessary in patients with hepatic impairment.</p><p><strong>Method of administration</strong></p><p>Zevtera must be reconstituted and then further diluted (see section 6.6) prior to administration by intravenous infusion over a period of 2 hours.</p><p>Precipitation can occur when Zevtera is mixed with calcium-containing solutions in the same intravenous administration line. Therefore, Zevtera and calcium-containing solutions, except Lactated Ringer&rsquo;s solution for injection, must not be mixed or administered simultaneously in the same intravenous line (see sections 4.4, 6.2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

Hypersensitivity to the cephalosporin class of antibacterials.

Immediate and severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or carbapenems).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reactions</u></p><p>As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported. In case of severe hypersensitivity reactions, treatment with Zevtera must be discontinued immediately and adequate emergency measures must be initiated.</p><p>Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to Zevtera, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if Zevtera is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p><u>Dosing above the recommended dose range</u></p><p>There is no clinical experience with Zevtera doses higher than the recommended 500 mg administered every eight hours.</p><p><u>Patients with pre-existing seizure disorders</u></p><p>Seizures have been associated with the use of Zevtera. Seizures occurred most commonly in patients with pre-existing CNS/seizure disorders during treatment with Zevtera. Therefore caution is advised when treating these patients.</p><p><em><u>Clostridioides difficile </u></em><u>-associated diarrhoea</u></p><p>Antibacterial agent-associated colitis and pseudomembranous colitis have been reported with the use of Zevtera and may range in severity from mild to life-threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of Zevtera (see section 4.8). Discontinuation of therapy with Zevtera and the administration of specific treatment for <em>Clostridioides</em> <em>difficile</em> should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p><u>Superinfection with non-susceptible organisms</u></p><p>The use of Zevtera may result in overgrowth of non-susceptible organisms, including fungi. Appropriate measures should be taken if evidence of superinfection occurs during therapy.</p><p><u>Renal toxicity in animals</u></p><p>In animals, reversible renal toxicity was observed at high doses of Zevtera and was associated with precipitation of drug-like material in the distal tubules (see section 5.3). Although the clinical significance of this observation is unknown, it is advisable to correct hypovolaemia to maintain normal urinary output in patients receiving Zevtera.</p><p><u>Precipitation with calcium-containing solutions</u></p><p>Precipitation can occur when Zevtera is mixed with calcium-containing solutions in the same intravenous administration line. Therefore, Zevtera and calcium-containing solutions, except Lactated Ringer&rsquo;s solution for injection, must not be mixed or administered simultaneously in the same intravenous line (see section 6.2).</p><p><u>Limitations of clinical data</u></p><p>There is no experience with ceftobiprole in the treatment of HAP (excluding VAP) and CAP in HIV- positive patients, patients with neutropenia, immunocompromised patients, and patients with myelosuppression. Caution is advised when treating such patients.</p><p><em>Patients with ventilator-associated pneumonia (VAP)</em></p><p>Zevtera has not been shown to be effective in the treatment of patients with VAP. Zevtera should not be initiated in patients with VAP (see Section 5.1). In addition, on the basis of a post-hoc analysis showing a trend in favour of ceftobiprole, it is recommended that in patients with hospital-acquired pneumonia (HAP) who subsequently require ventilation, Zevtera should be used with caution.</p><p><u>Clinical efficacy against specific pathogens</u></p><p><em>Susceptibility to Enterobacteriaceae</em></p><p>Ceftobiprole, like other cephalosporins is susceptible to hydrolysis that may be produced by Enterobacteriaceae including many of the extended-spectrum beta-lactamases (ESBLs), serine carbapenemases, class B metallo-beta-lactamases (among others). Therefore, information on the prevalence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) should be taken into consideration when selecting Zevtera for treatment (see section 5.1).</p><p><u>Interference with serological testing</u></p><p><em>Direct antiglobulin test (Coombs test) seroconversion and potential risk of haemolytic anaemia</em></p><p>The development of a positive direct antiglobulin test may occur during treatment with a cephalosporin. In clinical studies there was no evidence of haemolytic anaemia. However, the possibility that haemolytic anaemia may occur in association with Zevtera treatment cannot be ruled out. Patients experiencing anaemia during or after treatment with Zevtera should be investigated for this possibility.</p><p><u>Potential interference&nbsp;&nbsp; with serum creatinine test</u></p><p>It is not known whether ceftobiprole, like some other cephalosprins, interferes with the alkaline picrate assay to measure serum creatinine (Jaff&eacute; reaction), which may lead to erroneously high creatinine measurements. During treatment with Zevtera it is recommended that an enzymatic method of measuring serum creatinine be used.</p><p><u>Potential interference with urine glucose test</u></p><p>During treatment with Zevtera it is recommended that an enzymatic method to detect glucosuria be used, because of potential interference with tests using the copper reduction technique.</p><p><u>Zevtera contains sodium</u></p><p>Zevtera contains sodium. Zevtera 500 mg Powder for Concentrate for Solution for Infusion contains approximately 1.3 mmol (29 mg) sodium per dose. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro </em>studies have been carried out to investigate potential interactions at the level of CYP enzymes. However, as the concentrations of ceftobiprole used in these studies were limited by solubility, the potential for CYP drug interactions cannot be ruled out.</p><p><em>In vitro </em>studies showed that ceftobiprole inhibits OATP1B1 and OATP1B3 with IC50s of 67.6 &micro;M and 44.1 &micro;M, respectively. Zevtera may increase concentrations of drugs eliminated by OATP1B1 and OATP1B3, such as statins (pitavastin, pravastatin, rosuvastatin), glyburide, and bosentan.</p><p>No clinical interaction studies have been performed. Caution is advised when Zevtera is administered together with drugs with narrow therapeutic index.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate and well-controlled studies with Zevtera in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).</p><p>As no data in exposed human pregnancies are available, Zevtera should not be used during pregnancy unless strictly necessary.</p><p><u>Breast-feeding</u></p><p>Animal studies have shown the excretion of ceftobiprole/metabolites in milk at low concentrations. It is unknown whether ceftobiprole is excreted in human milk and the risk of diarrhoea and fungal infection of the mucous membranes in the breast-fed infant cannot be excluded. The possibility of sensitisation should be taken into account. A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from Zevtera therapy, taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>The effects of ceftobiprole medocaril on fertility in humans have not been studied. Animal studies with ceftobiprole medocaril do not indicate harmful effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, since dizziness is a common undesirable effect, driving and using machines is not recommended while on treatment with Zevtera.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In therapeutic clinical studies in adults, 1,668 subjects received Zevtera. Within these trials there were a total of 1,239 subjects (696 subjects in community-acquired pneumonia and nosocomial pneumonia, and 543 subjects in complicated skin and soft tissue infections, cSSTIs) who received 500 mg three times daily, 389 subjects (cSSTIs) who received 500 mg twice daily and 40 subjects (cSSTIs) who received 750 mg twice daily.</p><p>The most common adverse reactions occurring in &ge; 3% of patients treated with Zevtera were nausea, vomiting, diarrhoea, infusion site reactions, hypersensitivity (including urticaria, pruritic rash and drug hypersensitivity) and dysgeusia.</p><p>Less frequently reported, but more serious, adverse reactions include thrombocytopenia, agranulocytosis, anaphylaxis, <em>Clostridioides</em> <em>&nbsp;</em><em>difficile</em>, colitis, convulsion, agitation (including anxiety, panic attacks and nightmares), and renal failure.</p><p>Paediatric population</p><p>In one therapeutic clinical study in paediatric patients with community-acquired or nosocomial pneumonia, 94 subjects aged 3 months to 17 years received Zevtera. In two other clinical studies, 64 subjects aged 3 months to 17 years and 15 subjects aged 0 (birth) to &lt; 3 months received a single dose of Zevtera. Overall, the safety profile in paediatric patients was similar to that observed in the adult population.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions were reported during therapy and during follow-up with frequencies corresponding to very common (1/10); common (1/100 to &lt; 1/10); uncommon (1/1,000 to &lt; 1/100); rare (1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data):</p><p>Adverse reactions from clinical studies and post-marketing reports</p><table border="1" cellspacing="0" cellpadding="0" style="width:752px"><tbody><tr><td style="vertical-align:top; width:298px"><p><strong><em>System Organ Class</em></strong></p></td><td style="vertical-align:top; width:453px"><p><strong>Frequency: adverse events</strong></p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Infections and infestations</em></p></td><td style="vertical-align:top; width:453px"><p>Common: Fungal infection (including vulvovaginal, oral and cutaneous fungal infections)</p><p>Uncommon:&nbsp;<em>Clostridioides difficile</em>&nbsp;colitis (including pseudomembranous colitis)</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Uncommon: Eosinophilia, leukopenia, anaemia, thrombocytosis, thrombocytopenia</p><p>Not known: Agranulocytosis</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Common: Hypersensitivity reactions (including urticaria, pruritic rash and drug hypersensitivity)</p><p>Uncommon: Anaphylactic reactions</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Common: Hyponatraemia</p><p>Uncommon: Hypokalaemia</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Psychiatric disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Uncommon: Insomnia, agitation (including anxiety, panic attacks and nightmares)</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Common: Dysgeusia, headache, dizziness, somnolence</p><p>Uncommon: Convulsions (including seizure, epilepsy, generalized tonic-clonic seizure, myoclonic epilepsy, myoclonus, seizure like phenomena and status epilepticus)</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Uncommon: Dyspnoea, pharyngolaryngeal pain, asthma</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Common: Nausea, vomiting, diarrhoea, abdominal pain, dyspepsia</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Hepatobiliary disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Common: Hepatic enzymes increased (including AST, ALT, LDH and alkaline phosphatase)</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Common: Rash (including macular, papular, maculo-papular and generalised rash), pruritus</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Uncommon: Muscle spasms</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top; width:453px"><p>Uncommon: Renal failure (including potential interactions with nephrotoxic drugs)</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top; width:453px"><p>Common: Infusion site reactions</p><p>Uncommon: Peripheral oedema</p></td></tr><tr><td style="vertical-align:top; width:298px"><p><em>Investigations</em></p></td><td style="vertical-align:top; width:453px"><p>Uncommon: Blood triglycerides increased, blood creatinine increased, blood glucose increased</p><p>Not known: Coombs Direct Test Positive</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information on overdosage with Zevtera in humans is not available. The highest total daily dose administered in Phase 1 trials was 3 g (1 g every 8 hours). If overdosage should occur, it should be treated symptomatically. Ceftobiprole plasma concentrations can be reduced by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other cephalosporins, ATC code: J01DI01</p><p><u>Mechanism of Action</u></p><p>Ceftobiprole exerts bactericidal activity through binding to important penicillin-binding proteins (PBPs) in susceptible species. In Gram-positive bacteria, including methicillin-resistant <em>Staphylococcus aureus </em>(MRSA), Ceftobiprole binds to PBP2a. Ceftobiprole has demonstrated in vitro activity against strains with divergent <em>mec</em><em>A </em>homolog (<em>mec</em><em>C or mecA</em>LGA251). Ceftobiprole also binds to PBP2b in <em>Streptococcus pneumoniae </em>(penicillin-intermediate), PBP2x in <em>S. pneumoniae </em>(penicillin resistant), and to PBP5 in <em>Enterococcus faecalis</em>.</p><p><u>Mechanisms of Resistance</u></p><p>Ceftobiprole is inactive against strains of Enterobacteriaceae that express Ambler class A &beta;-lactamases, especially TEM, SHV and CTX-M type extended-spectrum &beta;-lactamases (ESBL) and the KPC-type carbapenemases, Ambler class B&nbsp; &beta;-lactamases and Ambler class D &beta;-lactamases, especially ESBL variants and carbapenemases (OXA-48).&nbsp; Ceftobiprole is also inactive against strains that have high levels of expression of Ambler class C &beta;-lactamases.</p><p>Ceftobiprole is inactive against strains of <em>P. aeruginosa </em>that express enzymes belonging to Ambler class A (e.g., PSE-1), Ambler class B (e.g., IMP-1, VIM-1, VIM-2) and Ambler class D (e.g., OXA- 10). It is also inactive against isolates that have acquired mutations in regulatory genes leading to de-repressed levels of expression of the chromosomal Ambler class C &beta;-lactamase, or over-expression of the Mex XY efflux pump.</p><p>Ceftobiprole is inactive against strains of <em>Acinetobacter </em>spp. that express enzymes belonging to Ambler class A (e.g., VEB-1), Ambler class B (e.g., IMP-1, IMP-4) Ambler class D (e.g., OXA-25, OXA-26), or that have de-repressed levels of expression of the chromosomal Ambler class C &beta;- lactamase.</p><p><u>Susceptibility testing breakpoints</u></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>MIC breakpoints (mg/ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pathogen</strong></p></td><td style="vertical-align:top"><p>Susceptible (&le; S)</p></td><td style="vertical-align:top"><p>Resistant (R &gt;)</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus&nbsp; </em>&nbsp;(including MRSA)</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriaceae</p></td><td style="vertical-align:top"><p>0.25</p></td><td style="vertical-align:top"><p>0.25</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas aeruginosa</em></p></td><td style="vertical-align:top"><p>IE<sup>a</sup></p></td><td style="vertical-align:top"><p>IE<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Non-species specific breakpoint<sup>b</sup></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a </sup>Insufficient evidence.</p><p><sup>b </sup>Based on the PK/PD target for Gram-negative organisms.</p></td></tr></tbody></table><p><u>PK/PD relationship</u></p><p>As with other beta-lactam antimicrobial agents, the percent time above the minimum inhibitory concentration (MIC) of the infecting organism over the dosing interval (%T &gt; MIC) has been shown to be the parameter that best correlates with the efficacy of ceftobiprole.</p><p><u>Clinical efficacy against specific pathogens</u></p><p>Efficacy has been demonstrated in clinical studies against the following pathogens in patients with HAP (not including VAP) and CAP that were susceptible to ceftobiprole in vitro:</p><ul><li><em>Staphylococcus aureus </em>(including MRSA)</li><li><em>Streptococcus pneumoniae </em>(including MDRSP)</li><li><em>Escherichia coli</em></li><li><em>Klebsiella pneumoniae</em></li></ul><p><u>Antibacterial activity against other relevant pathogens</u></p><p>Clinical efficacy has not been established against the following pathogens, although in vitro studies suggest that they would often be susceptible to ceftobiprole in the absence of an acquired mechanism of resistance:</p><ul><li><em>Acinetobacter spp. </em></li><li><em>Citrobacter spp. </em></li><li><em>Enterobacter spp. </em></li><li><em>Haemophilus influenzae </em></li><li><em>Klebsiella oxytoca </em></li><li><em>Moraxella catarrhalis </em></li><li><em>Morganella morganii </em></li><li><em>Proteus mirabilis </em></li><li><em>Providencia spp. </em></li><li><em>Pseudomonas spp. </em></li><li><em>Serratia </em>spp<em>.</em></li></ul><p><em>In vitro </em>data indicate that the following species are not susceptible to ceftobiprole:</p><ul><li><em>Chlamydophila (Chlamydia) pneumoniae</em></li><li><em>Burkholderia cepacia complex </em></li><li><em>Mycoplasma pneumoniae </em></li><li><em>Mycobacteria</em></li><li><em>Nocardia spp</em></li><li><em>Stenotrophomonas maltophilia</em></li></ul><p><u>Data from clinical studies</u></p><ul><li><em>Nosocomial</em> pneumonia</li></ul><p>Zevtera demonstrated efficacy in a well-controlled randomised Phase 3 study in patients with HAP. Non-inferiority between Zevtera and the comparator group could not be demonstrated in patients with VAP (i.e., patients who develop pneumonia &gt; 48 hours after onset of ventilation). In VAP, clinical cure rates in Zevtera treated patients were 37.7% in the Zevtera group (20 out of 53 patients) compared to 55.9% in the ceftazidime plus linezolid group (33 out of 59 patients), see also sections 4.1 and 4.4</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Plasma concentrations</u></p><p>The mean pharmacokinetic parameters of Zevtera in healthy adults for a single 500 mg dose administered as a 2-hour infusion and multiple 500 mg doses administered every 8 hours as 2-hour infusions are summarised in Table 1(see section 4.2). Pharmacokinetic characteristics were similar with single and multiple dose administration.</p><p><strong>Mean (standard deviation) pharmacokinetic parameters of Zevtera in healthy adults</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:996px"><tbody><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top; width:359px"><p><strong>Single 500 mg dose administered as a 120-minute infusion</strong></p></td><td style="vertical-align:top; width:472px"><p><strong>Multiple 500 mg doses administered every 8 hours as 120 minute infusions</strong></p></td></tr><tr><td style="vertical-align:top"><p>C<sub>m</sub><sub>ax</sub>&nbsp;(&micro;g/ml)</p></td><td style="vertical-align:top; width:359px"><p>29.2 (5.52)</p></td><td style="vertical-align:top; width:472px"><p>33.0 (4.83)</p></td></tr><tr><td style="vertical-align:top"><p>AUC (&micro;g&bull;h/ml)</p></td><td style="vertical-align:top; width:359px"><p>90.0 (12.4)</p></td><td style="vertical-align:top; width:472px"><p>102 (11.9)</p></td></tr><tr><td style="vertical-align:top"><p>t <sub>1/2</sub>&nbsp;(hours)</p></td><td style="vertical-align:top; width:359px"><p>3.1 (0.3)</p></td><td style="vertical-align:top; width:472px"><p>3.3 (0.3)</p></td></tr><tr><td style="vertical-align:top"><p>CL (ml/min)</p></td><td style="vertical-align:top; width:359px"><p>4.89 (0.69)</p></td><td style="vertical-align:top; width:472px"><p>4.98 (0.58)</p></td></tr></tbody></table><p><u>Distribution</u></p><p>Ceftobiprole binds minimally (16%) to plasma proteins and binding is independent of concentration. Ceftobiprole steady-state volume of distribution (18 litres) approximates extracellular fluid volume in healthy adults.</p><p><u>Metabolism</u></p><p>The active substance of Zevtera is ceftobiprole medocaril sodium, which is the pro-drug of the active moiety ceftobiprole. Conversion from the prodrug ceftobiprole medocaril sodium, to the active moiety ceftobiprole, occurs rapidly and is mediated by non-specific plasma esterases. Prodrug concentrations are negligible and are measurable in plasma and urine only during infusion. The metabolite resulting from the cleavage of the prodrug is diacetyl which is an endogenous human compound.</p><p>Ceftobiprole undergoes minimal metabolism to the open-ring metabolite, which is microbiologically inactive. Systemic exposure of the open-ring metabolite was considerably lower than for ceftobiprole, accounting for approximately 4% of the parent exposure in subject with a normal renal function.</p><p><em>In vitro </em>studies demonstrated that ceftobiprole is an inhibitor of the hepatocyte uptake transporters OATP1B1 and OATP1B3, but is not an inhibitor of PgP, BCRP, MDR1, MRP2, OAT1, OAT3, OCT1 or OCT2. Ceftobiprole is potentially a weak substrate of the renal tubule cells uptake transporters OAT1 and OCT2.</p><p>Ceftobiprole protein binding is low (16%) and is not a PgP inhibitor or substrate. The potential for other drugs to interact with ceftobiprole is minimal, since only a small fraction of ceftobiprole is metabolised. Therefore, no relevant drug-drug interactions are anticipated (see section 4.5).</p><p>Since ceftobiprole does not undergo tubular secretion and only a fraction is reabsorbed, renal drug-drug interactions are not expected.</p><p><u>Elimination</u></p><p>Ceftobiprole is eliminated primarily unchanged by renal excretion, with a half-life of approximately 3 hours. The predominant mechanism responsible for elimination is glomerular filtration, with some active reabsorption. Following single dose administration in healthy adults, approximately 89% of the administered dose is recovered in the urine as active ceftobiprole (83%), the open-ring metabolite (5%) and ceftobiprole medocaril (&lt;1%).</p><p><u>Linearity/non-linearity</u></p><p>Ceftobiprole exhibits linear and time-independent pharmacokinetics. The C<sub>max</sub> and AUC of Zevtera increase in proportion to dose over a range of 125 mg to 1 g. Steady-state active substance concentrations are attained on the first day of dosing; no appreciable accumulation occurs with every- 8-hour dosing in subjects with normal renal function.</p><p><u>Pharmacokinetic/Pharmacodynamic&nbsp;&nbsp; Relationship</u></p><p>Similar to other beta-lactam antimicrobial agents, the time that the plasma concentration of Zevtera exceeds the minimum inhibitory concentration of the infecting organism (%T&gt;MIC) has been shown to best correlate with efficacy in clinical and pre-clinical pharmacokinetic/pharmacodynamic studies.</p><p><u>Special Populations</u></p><p><em>Renal impairment</em></p><p>The estimation of creatinine clearance should be based on the Cockcroft-Gault formula using actual body weight in adult patients and the Schwartz formula in paediatric patients. During treatment with ceftobiprole it is recommended that an enzymatic method of measuring serum creatinine be used (see section 4.4).</p><p>The pharmacokinetics of ceftobiprole are similar in healthy adults and subjects with mild renal impairment (CL<sub>CR</sub>&nbsp;50 to 80 ml/min). Ceftobiprole AUC was 2.5- and 3.3-fold higher in subjects with moderate (CL<sub>CR</sub>&nbsp;30 to &lt; 50 ml/min) and severe (CL<sub>CR</sub>&nbsp;&lt; 30 ml/min) renal impairment, respectively, than in healthy adults with normal renal function.</p><p>Dosage adjustment is recommended in patients with moderate to severe renal impairment (see section 4.2). Dose recommendations for term neonates, infants, children, and adolescents are based on pharmacokinetic modelling</p><p><em>End-stage renal disease requiring dialysis</em></p><p>AUCs of ceftobiprole and of the microbiologically inactive ring-opened metabolite are substantially increased in adult patients with end-stage renal disease who require haemodialysis compared with healthy adults. In a study where six adult subjects with end-stage renal disease on haemodialysis received a single dose of 250 mg Zevtera by intravenous infusion, ceftobiprole was demonstrated to be haemodialysable with an extraction ratio of 0.7 (see section 4.2).</p><p>There is insufficient information to recommend dosage adjustment in paediatric patients with CL<sub>CR</sub>&nbsp;&lt; 10 mL/min/1.73 m2&nbsp;or end-stage renal disease requiring dialysis.</p><p><em>Patients with creatinine clearance &gt; 150 ml/min</em></p><p>Ceftobiprole systemic clearance (CL<sub>SS</sub>) was 40% greater in adult subjects with a CL<sub>CR</sub>&nbsp;&gt; 150 ml/min compared to subjects with a normal renal function (CL<sub>CR</sub>&nbsp;= 80-150 ml/min). Volume of distribution was 30% larger. In this population, based on pharmacokinetic/pharmacodynamic considerations, prolongation of duration of infusion is recommended (see section 4.2).</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of ceftobiprole in patients with hepatic impairment have not been established. As ceftobiprole undergoes minimal hepatic metabolism and is predominantly excreted unchanged in the urine, the clearance of Zevtera is not expected to be affected by hepatic impairment (see section 4.2).</p><p><em>Elderly</em></p><p>Population pharmacokinetic data showed that age as an independent parameter has no effect on the pharmacokinetics of ceftobiprole. Dosage adjustment is not considered necessary in elderly patients with normal renal function (see section 4.2).</p><p><em>Paediatric population</em></p><p>Population pharmacokinetic data showed that glomerular filtration rate maturation has an effect on the pharmacokinetics of ceftobiprole in paediatric patients aged 1 year and younger. and dDose adjustments are required for term neonates, infants, children, and adolescents with body weight &lt; 50 kg (see section 4.2).</p><p><u>Plasma concentrations in paediatric population</u></p><p>The mean exposures to Zevtera in paediatric subjects with normal renal function based on population PK modelling are summarised below (see section 4.2) and are similar to the mean exposures observed in adults.</p><p><strong>Mean (standard deviation) pharmacokinetic parameters of Zevtera in paediatric subjects predicted from population PK modelling</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Age group</strong></p></td><td style="vertical-align:top"><p><strong>Dosing regimen</strong></p></td><td style="vertical-align:top"><p><strong>Cmax (&micro;g/mL)</strong></p></td><td style="vertical-align:top"><p><strong>AUC (h.&micro;g/mL)</strong></p></td></tr><tr><td><p>Birth to &lt;3 months</p></td><td style="vertical-align:bottom"><p>15 mg/kg q12h<sup>a</sup></p></td><td style="vertical-align:bottom"><p>31.1 (7.05)</p></td><td style="vertical-align:bottom"><p>298 (66.4)</p></td></tr><tr><td><p>3 month to &lt;2 years</p></td><td style="vertical-align:bottom"><p>15 mg/kg q8h</p></td><td style="vertical-align:bottom"><p>30.3 (5.32)</p></td><td style="vertical-align:bottom"><p>278 (69.9)</p></td></tr><tr><td><p>2 to &lt;6 years</p></td><td style="vertical-align:bottom"><p>15 mg/kg q8h</p></td><td style="vertical-align:bottom"><p>30.8 (4.98)</p></td><td style="vertical-align:bottom"><p>266 (55.3)</p></td></tr><tr><td><p>6 to &lt;12 years</p></td><td style="vertical-align:bottom"><p>15 mg/kg q8h</p></td><td style="vertical-align:bottom"><p>35.2 (5.94)</p></td><td style="vertical-align:bottom"><p>312 (68.7)</p></td></tr><tr><td><p>12 to &lt;18 years</p></td><td style="vertical-align:bottom"><p>10 mg/kg q8h</p></td><td style="vertical-align:bottom"><p>26.6 (4.92)</p></td><td style="vertical-align:bottom"><p>245 (56.9)</p></td></tr><tr><td><p>Adults</p></td><td style="vertical-align:bottom"><p>500 mg q8h</p></td><td style="vertical-align:bottom"><p>33.0 (4.83)</p></td><td style="vertical-align:bottom"><p>306 (35.7)</p></td></tr></tbody></table><p>a - Patients with a body weight &lt; 4 kg given 10 mg/kg q12h as a 2-h infusion.</p><p><em>Gender</em></p><p>Systemic exposure to ceftobiprole was higher in adult females than adult males (21% for C<sub>max</sub> and 15% for AUC), however the %T&gt;MIC was similar in both males and females. Therefore, dosage adjustments based on gender are not considered necessary.</p><p><em>Race</em></p><p>Population pharmacokinetic analyses (including Caucasians, Black and Other groups) and a dedicated pharmacokinetic study in healthy Japanese adults showed no effect of race on the pharmacokinetics of ceftobiprole. Therefore, dosage adjustments based on race are not considered necessary.</p><p><em>Body weight</em></p><p>A study was performed in morbidly obese subjects. No dose adjustments based on body weight are required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reversible renal toxicity in the distal tubules due to precipitation of drug-like material was observed at high doses only in small animals such as rats and marmosets and after bolus administration. Absence of kidney toxicity was observed in animals at urinary concentrations up to 12 times higher than those observed in humans at the therapeutic dose. Convulsions were observed after both single and multiple doses at exposures of six times the human exposure and higher, based on C<sub>max</sub></p><p>Infusion-site irritation leading to thrombus formation was observed in small animals (rats and marmosets) but not in dogs. In a pre- and post-natal development study in rats, litter size and survival up to 4 days postpartum were decreased at maternally toxic doses. The relevance of all these findings for humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Citric acid monohydrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>This medicinal product must not be mixed or administered simultaneously with calcium-containing solutions (except Lactated Ringer&rsquo;s solution for injection). See sections 4.2, 4.4, 6.6.</p><p>This medicinal product should not be simultaneously administered via a Y site with:</p><p>Acyclovir sodium, Amikacin sulphate, Amiodarone hydrochloride, Amphotericin B (colloidal),&nbsp; Calcium gluconate, Caspofungin acetate, Ciprofloxacin, Cisatracurium besylate, Diazepam, Diltiazem hydrochloride, Diphenhydramine hydrochloride, Dobutamine hydrochloride, Dopamine hydrochloride, Esomeprazole sodium, Famotidine, Filgrastim, Gentamicin sulphate, Haloperidol lactate, Hydromorphone hydrochloride, Hydroxyzine hydrochloride, Insulin human regular, Insulin lispro, Labetalol hydrochloride, Levofloxacin, Lidocaine hydrochloride, Magnesium sulphate, Meperidine hydrochloride, Metoclopramide hydrochloride, Midazolam hydrochloride, Milrinone lactate, Morphine sulphate, Moxifloxacin hydrochloride, Ondansetron hydrochloride, Pantoprazole sodium, Potassium phosphates, Promethazine hydrochloride, Remifentanil hydrochloride, Sodium phosphates, Tobramycin sulphate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials
48 months. 

After reconstitution
Chemical and physical in-use stability of the reconstituted solution (50 mg/ml) has been demonstrated for 1 hour at 25°C and up to 24 hours at 2-8ᵒC.

After dilution
Chemical and physical in-use stability data support the total times for reconstitution and infusion of 2 mg/ml or 4 mg/ml ceftobiprole dilution solutions and are described in the tables below:

Use in adults and adolescents ≥ 12 years (2 mg/mL ceftobiprole): Total time by which reconstitution and infusion (including the period of infusion, see section 4.2) must be completed
Reconstitution solution diluent	                                  Infusion solution diluent	   Infusion solutions stored at 25°C	                                Infusion solutions stored at 2-8°C
		                                                                                                                                   Protected from light   NOT protected from light	Protected from light
50 mg/ml (5%) Dextrose solution for injection or
Water for injection	                                                    9 mg/ml (0.9%) Sodium              24 hours                     8 hours                                 	96 hours
                                                                                           chloride solution for injection	
                                                                                                                                     
	                                                                                    50 mg/ml (5%) Dextrose 	      12 hours                     8 hours                                 	96 hours
                                                                                            solution for injection
	                                                                                    Lactated Ringer's                           24 hours	                  8 hours	                                 Do not refrigerate
                                                                                             solution for injection

Use in children, infants, and neonates (< 12 years) (4 mg/ml ceftobiprole): Total time by which reconstitution and infusion (including the period of infusion, see section 4.2) must be completed
Reconstitution solution diluent	                          Infusion solution diluent	                                         Infusion solutions stored at 25°C	Infusion solutions stored at 2-8°C
                                                                                                                                                                                NOT protected from light	                 Protected from light
50 mg/ml (5%) Dextrose solution for injection	50 mg/ml (5%) Dextrose solution for injection	 12 hours	                                          24 hours
Water for injection	                                                9 mg/ml (0.9%) Sodium chloride                       	 8 hours                                                    8 hours
                                                                                         solution for injection

From a microbiological point of view, unless the method of reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

The reconstituted and infusion solutions should not be frozen or exposed to direct sunlight.

If the infusion solution is stored in the refrigerator, it should be equilibrated to room temperature prior to administration. The infusion solution does not need to be protected from light during administration.

The infusion solution should be prepared and used as defined in section 6.6.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2-8ᵒC).</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions of the reconstituted and/or diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20 ml clear glass vials fitted with grey elastomeric closures and aluminum seals with plastic flip-off caps.</p><p>Pack size: 10 Vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each vial is for single use only.</p><p>Zevtera must be reconstituted and then further diluted prior to infusion.</p><p><em>Step 1. Reconstitution</em></p><p>For adult and paediatric patients &ge; 12 years who require an infusion solution with a ceftobiprole concentration of 2 mg/ml, the lyophilized powder should be reconstituted with 10 ml of sterile water for injections or 50 mg/ml (5%) dextrose solution for injection.</p><p>For paediatric patients &lt; 12 years who require an infusion solution with a ceftobiprole concentration of 4 mg/ml, the lyophilized powder must be reconstituted either with 10 ml 50 mg/ml (5%) dextrose&nbsp; solution for injection if further dilution with the same diluent solution (i.e., 50 mg/ml (5%) dextrose solution for injection) is used, or with 10 ml of water for injection if further dilution with 9 mg/ml (0.9%) sodium chloride solution for injection is used (see section 6.3 tables).</p><p>The vial should be shaken vigorously until complete dissolution, which in some cases may take up to 10 minutes. The volume of the resulting concentrate is approximately 10.6 ml. Any foam should be allowed to dissipate and the reconstituted solution should be inspected visually to ensure the product is in solution and particulate matter is absent. The reconstituted concentrate contains 50 mg/ml of ceftobiprole (as 66.7 mg/ml of ceftobiprole medocaril sodium) and must be further diluted prior to administration. It is recommended that the reconstituted solution be further diluted immediately. However, if this is not possible the reconstituted solution can be stored at room temperature for up to 1 hour, or in a refrigerator for up to 24 hours.</p><p><strong><em>Step 2. Dilution (infusion solution)</em></strong></p><p><strong>Use in adult and paediatric patients &ge; 12 years</strong></p><p><em>Preparation of 500 mg dose of Zevtera solution for infusion (2 mg/ml ceftobiprole)</em></p><p>10 ml of the reconstituted solution should be withdrawn from the vial and injected into a suitable container (e.g. PVC or PE infusion bags, glass bottles) containing 250 ml of 9 mg/ml (0.9%) sodium chloride solution for injection, dextrose 50 mg/mL (5%) solution for injection, or Lactated Ringer&#39;s solution for injection. The infusion solution should be gently inverted 5-10 times to form a homogenous solution.</p><p>Vigorous agitation should be avoided to prevent foaming.</p><p>In adults, the entire contents of the infusion bag should be infused to administer a 500 mg dose of Zevtera.</p><p>In paediatric patients &ge; 12 years, the volume to be administered is equivalent to the calculated dose in mg/kg but not exceeding a maximum of 500 mg of Zevtera (see section 4.2).</p><p><em>Preparation of 250 mg dose of Zevtera solution for infusion for adult patients with severe renal impairment</em></p><p>5 ml of the reconstituted solution should be withdrawn from the vial and injected into a suitable container (e.g. PVC or PE infusion bags, glass bottles) containing 125 ml of 9 mg/ml (0.9%) sodium chloride solution for injection, 50 mg/ml (5%) dextrose solution for injection, or Lactated Ringer&#39;s solution for injection. The infusion solution should be gently inverted 5-10 times to form a homogenous solution. Vigorous agitation should be avoided to prevent foaming. The entire contents of the infusion bag should be infused to administer a 250 mg dose of Zevtera.</p><p><strong>Use in paediatric patients &lt; 12 years</strong></p><p><em>Preparation of Zevtera solution for infusion at a concentration of 4 mg/ml of ceftobiprole</em></p><p>Administration via infusion bags, bottles or syringes:</p><p>The reconstituted solution prepared with 10 ml 50 mg/ml (5%) dextrose solution for injection must be diluted with the same diluent solution (i.e<em>.,</em>&nbsp;50 mg/ml (5%) dextrose solution for injection). The reconstituted solution prepared with 10 mL water for injection solution must be diluted with 9 mg/ml (0.9%) sodium chloride solution for injection.</p><p>10 ml should be withdrawn from an infusion container (e.g., PVC or PE infusion bags, glass bottles) containing 125 mL of diluent solution and replaced with 10 ml of the reconstituted solution withdrawn from the vial. The infusion solution should be gently inverted 5&ndash;10 times to form a homogenous solution. Vigorous agitation should be avoided to prevent foaming. The volume to be administered is equivalent to the calculated dose in mg/kg but not exceeding a maximum of 500 mg of Zevtera (see section 4.2).</p><p>For administration via a 50 ml syringe if the calculated dose does not exceed 200 mg, 4 mL of the reconstituted solution (equivalent to 200 mg ceftobiprole) prepared with 50 mg/ml (5%) dextrose solution for injection or water for injection should be withdrawn from the vial and diluted with 46 ml of the appropriate infusion solution diluent (see section 6.3). The infusion solution should be gently inverted 5&ndash;10 times to form a homogenous solution. Vigorous agitation should be avoided to prevent foaming. The volume to be administered is equivalent to the calculated dose in mg/kg but not exceeding a maximum of 500 mg of Zevtera (see section 4.2).</p><p><strong><em>Appearance of diluted solution</em></strong></p><p>The solution for infusion should be clear to slightly opalescent and yellowish in colour. The solution for infusion should be inspected visually for particulate matter prior to administration, and discarded if particulate matter is visible.</p><p>Detailed information on the time by which reconstitution, dilution and infusion must complete is provided in section 6.3.</p><p><strong><em>Disposal</em></strong></p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                19 October 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>